Showing results (361-370 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|February 17, 2012
Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 studyChandra P Belani, Thomas Brodowicz, Tudor E Ciuleanu, et al.
The Lancet. Oncology|February 14, 2012
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialAlfons J M van den Eertwegh, Jurjen Versluis, H Pieter van den Berg, et al.
The Lancet. Oncology|January 31, 2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Enric Carcereny, Radj Gervais, et al.
The Lancet. Oncology|March 10, 2012
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trialGarnet L Anderson, Rowan T Chlebowski, Aaron K Aragaki, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
The Lancet. Oncology|December 3, 2014
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trialPeter M Ellis, Frances A Shepherd, Michael Millward, et al.
The Lancet. Oncology|December 3, 2014
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trialSung Hoon Noh, Sook Ryun Park, Han-Kwang Yang, et al.
The Lancet. Oncology|December 3, 2014
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trialPeter Hoskin, Oliver Sartor, Joe M O'Sullivan, et al.
The Lancet. Oncology|December 3, 2014
Local treatments for metastases of renal cell carcinoma: a systematic reviewSaeed Dabestani, Lorenzo Marconi, Fabian Hofmann, et al.
The Lancet. Oncology|October 2, 2013
Is cancer gene therapy an empty suit?Malcolm K Brenner, Stephen Gottschalk, Ann M Leen, et al.
Pageof 336